Search

Your search keyword '"Thull DL"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Thull DL" Remove constraint Author: "Thull DL"
47 results on '"Thull DL"'

Search Results

1. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

2. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

3. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

4. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

5. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

6. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

7. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

8. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

9. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

10. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

11. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

12. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

13. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

14. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

15. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

16. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

17. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

18. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

19. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.

20. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

21. Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

22. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

23. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women.

24. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.

25. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

26. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

27. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

28. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

29. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

30. Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.

31. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

32. The FANCM :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

33. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

34. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.

35. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.

36. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

37. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.

39. A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer.

40. Long-term outcomes, branch-specific expressivity, and disease-related mortality in von Hippel-Lindau type 2A.

41. Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations.

42. Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism.

43. Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability.

44. Recognition and management of hereditary breast cancer syndromes.

45. Regulated expression of vasopressin gene by cAMP and phorbol ester in primary rat fetal hypothalamic cultures.

46. Second messengers involved in the regulation of corticotropin-releasing hormone mRNA and peptide in cultured rat fetal hypothalamic primary cultures.

47. Developmental expression of corticotropin releasing hormone messenger RNA and peptide in rat hypothalamus.

Catalog

Books, media, physical & digital resources